These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 21195878)

  • 21. Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy.
    Tai CJ; Lo HY; Hsu CH; Tai CJ; Liu WM
    Gynecol Oncol; 2006 Apr; 101(1):184-5. PubMed ID: 16413601
    [No Abstract]   [Full Text] [Related]  

  • 22. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.
    Persson MI; Gedda L; Jensen HJ; Lundqvist H; Malmström PU; Tolmachev V
    Oncol Rep; 2006 Mar; 15(3):673-80. PubMed ID: 16465429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: comparison with manual counting.
    Cai Z; Chattopadhyay N; Liu WJ; Chan C; Pignol JP; Reilly RM
    Int J Radiat Biol; 2011 Nov; 87(11):1135-46. PubMed ID: 21913819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in radiosensitivity between three HER2 overexpressing cell lines.
    Steffen AC; Göstring L; Tolmachev V; Palm S; Stenerlöw B; Carlsson J
    Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1179-91. PubMed ID: 18193218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visualization of HER2-specific breast cancer intratumoral heterogeneity using
    Sasada S; Kurihara H; Kinoshita T; Yoshida M; Honda N; Shimoi T; Shimomura A; Yonemori K; Shimizu C; Hamada A; Kanayama Y; Watanabe Y; Fujiwara Y; Tamura K
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2146-2147. PubMed ID: 28770275
    [No Abstract]   [Full Text] [Related]  

  • 26. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.
    Abbas N; Heyerdahl H; Bruland OS; Borrebæk J; Nesland J; Dahle J
    EJNMMI Res; 2011 Aug; 1(1):18. PubMed ID: 22214432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
    Larsen RH; Borrebaek J; Dahle J; Melhus KB; Krogh C; Valan MH; Bruland OS
    Cancer Biother Radiopharm; 2007 Jun; 22(3):431-7. PubMed ID: 17651051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Why should the clonogenic cell assay be prognostically important in ovarian cancer?
    Cannistra SA
    J Clin Oncol; 1991 Mar; 9(3):368-70. PubMed ID: 1999705
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers?
    Shah MA
    Lancet Oncol; 2017 Nov; 18(11):1433-1434. PubMed ID: 29037986
    [No Abstract]   [Full Text] [Related]  

  • 30. A new agent in the family of antibody-drug conjugates.
    Pivot X; Petit T
    Lancet Oncol; 2019 Aug; 20(8):1043-1044. PubMed ID: 31257178
    [No Abstract]   [Full Text] [Related]  

  • 31. Irradiation and monocyte function in patients with breast cancer.
    Taylor SA; Gordon MY; Currie GA; Shepherd VB
    Int J Radiat Oncol Biol Phys; 1979; 5(11-12):2063-7. PubMed ID: 544587
    [No Abstract]   [Full Text] [Related]  

  • 32. QnAs with H. Michael Shepard and Dennis J. Slamon.
    Davis TH
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):796-798. PubMed ID: 31888982
    [No Abstract]   [Full Text] [Related]  

  • 33. Alpha decay of 231U to levels in 227Th.
    Liang CF; Sheline RK; Paris P; Hussonois M; Ledu JF; Isabelle DB
    Phys Rev C Nucl Phys; 1994 Apr; 49(4):2230-2232. PubMed ID: 9969455
    [No Abstract]   [Full Text] [Related]  

  • 34. Modified poly-L-lysine for use as a clearing agent in pretargeted radioimmunotherapy.
    Timperanza C; Gustafsson-Lutz A; Bäck T; Green DJ; Lindegren S; Aneheim E
    EJNMMI Radiopharm Chem; 2024 Nov; 9(1):76. PubMed ID: 39538107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigen targeting and anti-tumor activity of a novel anti-CD146
    Lindland K; Malenge MM; Li RG; Wouters R; Bønsdorff TB; Juzeniene A; Dragovic SM
    Sci Rep; 2024 Oct; 14(1):25941. PubMed ID: 39472474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
    Böhnke N; Indrevoll B; Hammer S; Papple A; Kristian A; Briem H; Celik A; Mumberg D; Cuthbertson A; Zitzmann-Kolbe S
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):669-680. PubMed ID: 37882848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted thorium-227 conjugates as treatment options in oncology.
    Karlsson J; Schatz CA; Wengner AM; Hammer S; Scholz A; Cuthbertson A; Wagner V; Hennekes H; Jardine V; Hagemann UB
    Front Med (Lausanne); 2022; 9():1071086. PubMed ID: 36726355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
    Pallares RM; Abergel RJ
    Front Med (Lausanne); 2022; 9():1020188. PubMed ID: 36619636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and characterization of a time-domain optical tomography platform for mesoscopic lifetime imaging.
    Gao S; Li M; Smith JT; Intes X
    Biomed Opt Express; 2022 Sep; 13(9):4637-4651. PubMed ID: 36187247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusion of apoptosis-related protein Cytochrome c with anti-HER-2 single-chain antibody targets the suppression of HER-2+ breast cancer.
    Lu D; Guo Y; Hu Y; Wang M; Li C; Gangrade A; Chen J; Zheng Z; Guo J
    J Cell Mol Med; 2021 Nov; 25(22):10638-10649. PubMed ID: 34697906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.